Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475616 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending Dose Study of PCO371 in Healthy Volunteers
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02475616: Clinical Trial Phase 1 study, sponsored by Chugai Pharmaceutical.
NCT02475616 is a Phase 1 study that was terminated before completion, run by Chugai Pharmaceutical. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02475616, a Phase 1 study, was terminated before completion, sponsored by Chugai Pharmaceutical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in healthy adult males. Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.
Interventions
- DRUG Placebo
- DRUG PCO371
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Why NCT02475616 stopped before completion
NCT02475616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02475616 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02475616 about?
NCT02475616 is a clinical study titled "A Single Ascending Dose Study of PCO371 in Healthy Volunteers". This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in healthy adult males. Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.
What is the current status of trial NCT02475616?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02475616?
The interventions under investigation include: Placebo (DRUG), PCO371 (DRUG).
Who is sponsoring clinical trial NCT02475616?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02475616's enrollment target sits among peer trials
64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia